biotech / news / / The Economic Times
Moderna's first-quarter revenue surpassed estimates, driven by strong international COVID-19 vaccine sales.
Moderna's first-quarter revenue more than tripled to $389 million, driven by international COVID-19 vaccine sales.
KEY POINTS
- U.S. COVID-19 vaccine recommendations have become uncertain under Health Secretary Robert F. Kennedy Jr.
- Moderna received European approval for its combination COVID-flu vaccine, mCombriax, targeting a 2027 launch.
- Moderna forecasts Q2 revenue below analyst expectations, with a 50-50 split between U.S. and international sales.
- The company expects up to 10% revenue growth by 2026, with half from the U.S., down from 62% last year.
COMPANIES
Summarized by Newsio from The Economic Times. How we summarize →